Article
Drug-induced liver injury in humans: the case of ximelagatran.
Handbook of experimental pharmacology - 1 Jan 2010
Keisu M, Andersson T B
Abstract excerpt
Ximelagatran was the first orally available direct thrombin inhibitor under clinical development that also reached the market. Ximelagatran was tested in an extensive clinical programme. Short-term use (<12 days) in humans including the phase III clinical trials did not indicate any hepatotoxic potential. Increased hepatic enzyme levels were first observed at a higher frequency when evaluating the long-term (>35...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.